Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study

Zhou, Aiping; Sun, Yan; Zhang, W.; Jiang, Zhichao; Chen, B.; Zhao, Jian; Li, Z.; Wang, L.

doi:10.1093/annonc/mdz247.077

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The updated OS results for the ALTER 1202 study indicated that, in addition to the PFS benefit, median OS was significantly prolonged by about 2.4 months in the anlotinib group compared with the placebo group in patients with SCLC who had failed at least two lines of chemotherapy 9. Other studies, including ALTER 1102, NCT02586350, ALTER 0802, and ALTER 0203, confirmed that anlotinib was also efficacious in patients with esophageal squamous cell carcinoma,10 medullary thyroid carcinoma,11 hepatocellular carcinoma,12 and soft tissue sarcoma 13. Overall, these results suggest that anlotinib is a promising treatment option for patients with various solid tumors.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of advanced ovarian cancer with anlotinib: a case report

Zhang

Wang

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated clinical antitumor activity of anlotinib in various cancers. We report the case of an elderly woman with advanced ovarian cancer who received anlotinib after failure of multiple-line chemotherapy. A partial response was observed after six cycles of anlotinib monotherapy, with a reduction in the size of the metastases and significantly decreased serum CA125 levels from 1832.7 U/mL to 118.7 U/mL. She continued to take anlotinib, with a progression-free survival time of more than 4 months. Only mild hypertension was observed during the treatment. Anlotinib monotherapy may be a novel therapeutic option for patients with advanced ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful treatment of advanced ovarian cancer with anlotinib: a case report

Zhang

Wang

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…50 Anlotinib (targeting VEGFRs, EGFR, and FGFR) also showed a durable anti-tumor activity (ORR 4.6% and median time to progression 4.0–5.5 months) and manageable toxicity in a phase II study. 51 …”

Section: Tumor Angiogenesis In Hcc and The Rational Of Anti-angiogenimentioning

confidence: 99%

Targeting angiogenesis for liver cancer: Past, present, and future

2020

View full text Add to dashboard Cite

Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies.

show abstract

Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes

Zhang

Lin

et al. 2020

CGT

View full text Add to dashboard Cite

: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at advanced stage that can only benefit from systemic treatments. Although HCC is highly treatment resistant, significant achievements have been made in the molecular targeted therapy and immunotherapy of HCC. In addition to regorafenib, cabozantinib and ramucirumab were approved for the second-line targeted treatment by FDA after disease progression on sorafenib. Nivolumab failed to demonstrate remarkable benefit in overall survival (OS) as a first-line therapy, while pembrolizumab did not achieve pre-specified statistical significance in both OS and progression-free survival (PFS) as a second-line treatment. Combinations of targeted agents, immune checkpoint inhibitors and other interventions showed favorable results. In this review, we summarized the progress of systemic therapy in HCC and discussed the future directions of the treatment of HCC.

show abstract

Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study

Cited by 3 publications

References 0 publications

Successful treatment of advanced ovarian cancer with anlotinib: a case report

Successful treatment of advanced ovarian cancer with anlotinib: a case report

Targeting angiogenesis for liver cancer: Past, present, and future

Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes

Contact Info

Product

Resources

About